Publications by authors named "A Limaye"
Article Synopsis
- - Recent advancements in cytomegalovirus (CMV) prevention and treatment have emerged from pivotal clinical trials, focusing on tailored strategies for hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT).
- - The review highlights methods to boost CMV-specific immunity using vaccination, monoclonal antibodies, and virus-specific T-cells, alongside observational studies on CMV cell-mediated immunity assays to refine preventive and treatment approaches.
- - Emphasizing the need to enhance CMV-specific immunity is vital for reducing CMV's detrimental effects in transplant recipients, especially as infections in CAR-T therapy patients and other immunocompromised groups rise, although these areas are not covered in this review.
Chronic lung allograft dysfunction (CLAD) is the most common cause of long-term lung allograft failure. Several factors, including respiratory virus infection (RVI), have been associated with CLAD development, but the underlying mechanisms of these associations are not well understood. We hypothesize that RVI in lung transplant recipients elicits the development of donor-specific antibodies (DSAs), thus providing a mechanistic link between RVI and CLAD development.
View Article and Find Full Text PDFBackground: BK polyomavirus-associated nephropathy (BKPyVAN) is an important cause of allograft dysfunction and failure in kidney transplant recipients (KTRs) and there are no proven effective treatments. Case reports and in vitro data support the potential activity of cidofovir against BK polyomavirus (BKPyV).
Methods: We report the results of a phase I/II, double-blind, placebo-controlled randomized dose-escalation trial of cidofovir in KTRs with biopsy-confirmed BKPyVAN and estimated glomerular filtration rate ≥30 mL/min.
Introduction: Aflatoxin B1 (AFB1) is a potent hepatocarcinogenic mycotoxin found in animal feed and human food components. AFB1 contamination poses severe food safety and economic consequences.
Methods: In this study, we used a coumarin-selective medium to isolate bacterial strains that can remove AFB1.